AR021643A1 - Combinacion de cerivastatina y fibratos. - Google Patents
Combinacion de cerivastatina y fibratos.Info
- Publication number
- AR021643A1 AR021643A1 ARP990106332A ARP990106332A AR021643A1 AR 021643 A1 AR021643 A1 AR 021643A1 AR P990106332 A ARP990106332 A AR P990106332A AR P990106332 A ARP990106332 A AR P990106332A AR 021643 A1 AR021643 A1 AR 021643A1
- Authority
- AR
- Argentina
- Prior art keywords
- cerivastatin
- combination
- fibrates
- inhibitor
- diseases
- Prior art date
Links
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 title abstract 2
- 229960005110 cerivastatin Drugs 0.000 title abstract 2
- 229940125753 fibrate Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
La presente invencion se refiere a la combinacion del inhibidor de la 3-hidroxi-3-metil-glutaril-coenzima- A (inhibidor de la HMG-CoA), cerivastatina, confibratos y a su uso en la profilaxis y tratamiento de trastornos y enfermedades del metabolismode los lípidos así como de enfermedades causadas por ello.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19858789A DE19858789A1 (de) | 1998-12-18 | 1998-12-18 | Kombination von Cerivastatin und Fibraten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021643A1 true AR021643A1 (es) | 2002-07-31 |
Family
ID=7891784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106332A AR021643A1 (es) | 1998-12-18 | 1999-12-13 | Combinacion de cerivastatina y fibratos. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6511985B1 (es) |
| EP (1) | EP1140082A1 (es) |
| KR (1) | KR20010093845A (es) |
| CN (1) | CN1330544A (es) |
| AR (1) | AR021643A1 (es) |
| AU (1) | AU3035600A (es) |
| BR (1) | BR9916270A (es) |
| CA (1) | CA2355295A1 (es) |
| CO (1) | CO5160272A1 (es) |
| DE (1) | DE19858789A1 (es) |
| GT (1) | GT199900214A (es) |
| HN (1) | HN1999000208A (es) |
| IL (1) | IL143221A0 (es) |
| PE (1) | PE20001325A1 (es) |
| PL (1) | PL349389A1 (es) |
| SV (1) | SV1999000250A (es) |
| TR (1) | TR200101722T2 (es) |
| WO (1) | WO2000037078A1 (es) |
| ZA (1) | ZA200103918B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
| EP1361867B1 (en) * | 2001-02-22 | 2007-03-21 | Jagotec AG | Fibrate-statin combinations with reduced fed-fasted effects |
| WO2003013607A1 (en) * | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR |
| EP1414496B1 (en) | 2001-08-07 | 2010-10-20 | Galephar M/F | Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride |
| DE10200138A1 (de) * | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
| US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
| CA2753318A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives |
| WO2005046662A2 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
| EP1853249A2 (en) * | 2005-02-10 | 2007-11-14 | LifeCycle Pharma A/S | A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor |
| US8026377B2 (en) * | 2005-11-08 | 2011-09-27 | Ranbaxy Laboratories, Limited | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
| TW200811101A (en) * | 2006-07-14 | 2008-03-01 | Ranbaxy Lab Ltd | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
| BRPI0621942A2 (pt) * | 2006-08-04 | 2011-10-18 | Aska Pharm Co Ltd | preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação |
| TWI407955B (zh) | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| WO2023146320A1 (ko) * | 2022-01-28 | 2023-08-03 | 동광제약 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2494112B1 (es) | 1980-11-19 | 1986-01-10 | Laruelle Claude | |
| AU1422388A (en) | 1987-01-27 | 1988-08-10 | Warner-Lambert Company | Lipid regulating compositions |
| FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| CA2039763A1 (en) * | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| FR2737121B1 (fr) | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
| DE69837610T2 (de) * | 1997-07-31 | 2008-01-03 | Kos Life Sciences, Inc., Weston | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung |
-
1998
- 1998-12-18 DE DE19858789A patent/DE19858789A1/de not_active Ceased
-
1999
- 1999-11-30 HN HN1999000208A patent/HN1999000208A/es unknown
- 1999-12-06 KR KR1020017007596A patent/KR20010093845A/ko not_active Application Discontinuation
- 1999-12-06 AU AU30356/00A patent/AU3035600A/en not_active Abandoned
- 1999-12-06 TR TR2001/01722T patent/TR200101722T2/xx unknown
- 1999-12-06 CN CN99814627A patent/CN1330544A/zh active Pending
- 1999-12-06 EP EP99964522A patent/EP1140082A1/de not_active Withdrawn
- 1999-12-06 BR BR9916270-9A patent/BR9916270A/pt not_active Application Discontinuation
- 1999-12-06 PL PL99349389A patent/PL349389A1/xx not_active Application Discontinuation
- 1999-12-06 US US09/868,444 patent/US6511985B1/en not_active Expired - Fee Related
- 1999-12-06 IL IL14322199A patent/IL143221A0/xx unknown
- 1999-12-06 WO PCT/EP1999/009524 patent/WO2000037078A1/de not_active Application Discontinuation
- 1999-12-06 CA CA002355295A patent/CA2355295A1/en not_active Abandoned
- 1999-12-13 AR ARP990106332A patent/AR021643A1/es unknown
- 1999-12-16 PE PE1999001259A patent/PE20001325A1/es not_active Application Discontinuation
- 1999-12-16 GT GT199900214A patent/GT199900214A/es unknown
- 1999-12-16 CO CO99078829A patent/CO5160272A1/es unknown
- 1999-12-17 SV SV1999000250A patent/SV1999000250A/es unknown
-
2001
- 2001-05-15 ZA ZA200103918A patent/ZA200103918B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200101722T2 (tr) | 2001-11-21 |
| AU3035600A (en) | 2000-07-12 |
| HN1999000208A (es) | 2000-11-22 |
| ZA200103918B (en) | 2002-05-15 |
| US6511985B1 (en) | 2003-01-28 |
| SV1999000250A (es) | 2000-10-16 |
| KR20010093845A (ko) | 2001-10-29 |
| PL349389A1 (en) | 2002-07-15 |
| CO5160272A1 (es) | 2002-05-30 |
| BR9916270A (pt) | 2001-09-04 |
| WO2000037078A1 (de) | 2000-06-29 |
| CA2355295A1 (en) | 2000-06-29 |
| EP1140082A1 (de) | 2001-10-10 |
| GT199900214A (es) | 2001-06-08 |
| IL143221A0 (en) | 2002-04-21 |
| DE19858789A1 (de) | 2000-06-21 |
| CN1330544A (zh) | 2002-01-09 |
| PE20001325A1 (es) | 2000-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021643A1 (es) | Combinacion de cerivastatina y fibratos. | |
| BR0116470A (pt) | éteres de imidazoquinolina substituìdos com uréia | |
| HN2003000227A (es) | Inhibidores de quinasas | |
| ES2171746T3 (es) | Empleo de epinastina para el tratamiento de dolores. | |
| SV2001000004A (es) | Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa | |
| HN1999000125A (es) | Nuevos derivados sustituidos del pirazol | |
| HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
| GT200300149A (es) | Formulacion farmaceutica | |
| ECSP034568A (es) | Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona | |
| SE0001899D0 (sv) | New compounds | |
| PT1309589E (pt) | Compostos de ureia e metodos de utilizacao | |
| HN1999000066A (es) | Formulaciones farmaceuticas | |
| MEP42808A (en) | Use of flibanserin in the treatment of sexual disorders | |
| ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
| HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| HN2002000300A (es) | Nuevos derivados de piperazina | |
| TR200200260T2 (tr) | N-desmetilzopiklonlarının üretim ve kullanım yöntemleri | |
| ME00113B (me) | Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja | |
| BR0114903A (pt) | 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação | |
| ECSP044862A (es) | Pirenzepine ophthalmic gel | |
| SE9901077D0 (sv) | Novel use | |
| BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
| NI200300045A (es) | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. | |
| ES2170143T3 (es) | Composiciones que comprenden halofantrina en una forma especial. |